Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the National Medical Products Administration of China (NMPA) has granted Investigational New Drug (IND) approval for a Phase II clinical trial of BW-40202, an investigational siRNA therapy targeting complement factor B (CFB) for the treatment of paroxysmal nocturnal […]